{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu LY"],"funding":["NCATS NIH HHS","NIAID NIH HHS","NIAMS NIH HHS"],"pagination":["675-682.e1"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6233876"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["77(4)"],"pubmed_abstract":["<h4>Background</h4>Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs. Existing therapies are often inadequate. Prior reports have shown benefit of the Janus kinase (JAK) inhibitors.<h4>Objective</h4>To evaluate the efficacy of the JAK 1/3 inhibitor tofacitinib in the treatment of vitiligo.<h4>Method</h4>This is a retrospective case series of 10 consecutive patients with vitiligo treated with tofacitinib. Severity of disease was assessed by body surface area of depigmentation.<h4>Results</h4>Ten consecutive patients were treated with tofacitinib. Five patients achieved some repigmentation at sites of either sunlight exposure or low-dose narrowband ultraviolet B phototherapy. Suction blister sampling revealed that the autoimmune response was inhibited during treatment in both responding and nonresponding lesions, suggesting that light rather than immunosuppression was primarily required for melanocyte regeneration.<h4>Limitations</h4>Limitations include the small size of the study population, retrospective nature of the study, and lack of a control group.<h4>Conclusion</h4>Treatment of vitiligo with JAK inhibitors appears to require light exposure. In contrast to treatment with phototherapy alone, repigmentation during treatment with JAK inhibitors may require only low-level light. Maintenance of repigmentation may be achieved with JAK inhibitor monotherapy. These results support a model wherein JAK inhibitors suppress T cell mediators of vitiligo and light exposure is necessary for stimulation of melanocyte regeneration."],"journal":["Journal of the American Academy of Dermatology"],"pubmed_title":["Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure."],"pmcid":["PMC6233876"],"funding_grant_id":["R01 AR069114","UL1 TR001453","T32 AI095213"],"pubmed_authors":["Strassner JP","Harris JE","King BA","Liu LY","Refat MA"],"additional_accession":[]},"is_claimable":false,"name":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.","description":"<h4>Background</h4>Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs. Existing therapies are often inadequate. Prior reports have shown benefit of the Janus kinase (JAK) inhibitors.<h4>Objective</h4>To evaluate the efficacy of the JAK 1/3 inhibitor tofacitinib in the treatment of vitiligo.<h4>Method</h4>This is a retrospective case series of 10 consecutive patients with vitiligo treated with tofacitinib. Severity of disease was assessed by body surface area of depigmentation.<h4>Results</h4>Ten consecutive patients were treated with tofacitinib. Five patients achieved some repigmentation at sites of either sunlight exposure or low-dose narrowband ultraviolet B phototherapy. Suction blister sampling revealed that the autoimmune response was inhibited during treatment in both responding and nonresponding lesions, suggesting that light rather than immunosuppression was primarily required for melanocyte regeneration.<h4>Limitations</h4>Limitations include the small size of the study population, retrospective nature of the study, and lack of a control group.<h4>Conclusion</h4>Treatment of vitiligo with JAK inhibitors appears to require light exposure. In contrast to treatment with phototherapy alone, repigmentation during treatment with JAK inhibitors may require only low-level light. Maintenance of repigmentation may be achieved with JAK inhibitor monotherapy. These results support a model wherein JAK inhibitors suppress T cell mediators of vitiligo and light exposure is necessary for stimulation of melanocyte regeneration.","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Oct","modification":"2025-04-21T14:49:53.008Z","creation":"2019-03-27T00:06:58Z"},"accession":"S-EPMC6233876","cross_references":{"pubmed":["28823882"],"doi":["10.1016/j.jaad.2017.05.043"]}}